Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays

• Jonathan A. Lee ,

  Contributed equally to this work with: Jonathan A. Lee, Paul Shinn, Susan Jaken

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Paul Shinn ,

  Contributed equally to this work with: Jonathan A. Lee, Paul Shinn, Susan Jaken

  Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Susan Jaken ,

  Contributed equally to this work with: Jonathan A. Lee, Paul Shinn, Susan Jaken

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Sarah Oliver,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Francis S. Willard,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Steven Heidler,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Robert B. Peery,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Jennifer Oler,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Shaoyou Chu,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Noel Southall,

  Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Thomas S. Dexheimer,

  Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Jeffrey Smallwood,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Ruili Huang,

  Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Rajarshi Guha,

  Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Ajit Jadhav,

  Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Karen Cox,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Christopher P. Austin,

  Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Anton Simeonov,

  Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• G. Sitta Sittampalam,

  Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Saba Husain,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Natalie Franklin,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• David J. Wild,

  Affiliation Indiana University School of Informatics and Computing, Bloomington, Indiana, United States of America

  ⨯
• Jeremy J. Yang,

  Affiliation Indiana University School of Informatics and Computing, Bloomington, Indiana, United States of America

  ⨯
• Jeffrey J. Sutherland ,

  * E-mail: sutherland_jeffrey_james@lilly.com (JJS); craigt@mail.nih.gov (CJT)

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
•  [ ... ],
• Craig J. Thomas

  * E-mail: sutherland_jeffrey_james@lilly.com (JJS); craigt@mail.nih.gov (CJT)

  Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• [ view all ]
• [ view less ]